Skip to Content
Investing Specialists

2013: Readers Share Greatest Hits, Biggest Misses

Biotech rules and bonds disappoint for many Morningstar.com readers.

Mentioned: , , , , , , ,

By almost any measure, the year 2013 is going to go down in the books as a very good one for most investors. As December winds down, the S&P 500 is flirting with a gain of nearly 30%. Bonds have been much less distinguished, but not dreadful, with most core bond-fund types posting small losses for the year to date.

In a recent Morningstar.com Discuss forum thread, I asked readers to take stock of their biggest hits and misses for the year, and to share their reflections on their winners and losers. Not surprisingly, stocks and stock funds, many of which relate to the high-flying biotechnology sector, rated as many investors' biggest victories for the year. Bonds? Not so much.

To view this article, become a Morningstar Basic member.

Register for Free

Christine Benz does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.